Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clinic 71(3):209–249

Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33

Article  PubMed  Google Scholar 

The Global Cancer Observatory. united-kingdom-fact-sheets: World Health Organisation; 2021 [https://gco.iarc.fr/today/data/factsheets/populations/826-united-kingdom-fact-sheets.pdf.

Ismail-Khan R, Bui MM (2010) A review of triple-negative breast cancer. Cancer Control 17(3):173–176

Article  PubMed  Google Scholar 

De Giorgi U, Rosti G, Frassineti L, Kopf B, Giovannini N, Zumaglini F et al (2007) High-dose chemotherapy for triple negative breast cancer. Ann Oncol 18(1):202–203

Article  PubMed  Google Scholar 

Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agrawal V et al (2016) Outcomes of triple-negative breast cancers (TNBC) compared with non-TNBC: does the survival vary for all stages? World J Surg 40(6):1362–1372

Article  PubMed  Google Scholar 

Kumar P, Aggarwal R (2016) An overview of triple-negative breast cancer. Arch Gynecol Obstet 293(2):247–269

Article  PubMed  CAS  Google Scholar 

Ge J, Zuo W, Chen Y, Shao Z, Yu K (2021) The advance of adjuvant treatment for triple-negative breast cancer. Cancer Biol Med 19(2):187–201

PubMed  PubMed Central  Google Scholar 

Pomponio MK, Keele LJ, Fox KR, Clark AS, Matro JM, Shulman LN et al (2019) Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer? Breast Cancer Res Treat 177(1):137–143

Article  PubMed  CAS  Google Scholar 

Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2(3):322–329

Article  PubMed  PubMed Central  Google Scholar 

Morante Z, Ruiz R, Araujo JM, Pinto JA, Cruz-Ku GDL, Urrunaga-Pastor D et al (2021) Impact of the delayed initiation of adjuvant chemotherapy in the outcome of triple negative breast cancer. Clin Breast Cancer 21(3):239–46.e4

Article  PubMed  CAS  Google Scholar 

Suleman K, Almalik O, Haque E, Mushtaq A, Badran A, Alsayed A et al (2020) Does the timing of surgery after neoadjuvant therapy in breast cancer patients affect the outcome? Oncology 98(3):168–173

Article  PubMed  Google Scholar 

Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K et al (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24(9):1357–1362

Article  PubMed  Google Scholar 

Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Round G, Lawrenson R (2014) Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study. BMC Cancer 14:839

Article  PubMed  PubMed Central  Google Scholar 

Heeg E, Marang-van de Mheen PJ, Van Maaren MC, Schreuder K, Tollenaar R, Siesling S et al (2020) Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer. Int J Cancer 147(1):152–159

Article  PubMed  CAS  Google Scholar 

OfN S (2022) Ethnic group, England and Wales: Census 2021.

Smith-Graziani D, Lei X, Giordano SH, Zhao H, Karuturi M, Chavez-MacGregor M (2020) Delayed initiation of adjuvant chemotherapy in older women with breast cancer. Cancer Med 9(19):6961–6971

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cook P, Yin G, Ayeni FE, Eslick GD, Edirimanne S (2023) Does immediate breast reconstruction lead to a delay in adjuvant chemotherapy for breast cancer? A meta-analysis and systematic review. Clin Breast Cancer 23(5):e285–e295

Article  PubMed  CAS  Google Scholar 

Anna F, Becky W, Diana N, Jon S, Ruth HJ (2023) Relationship between ethnicity and stage at diagnosis in England: a national analysis of six cancer sites. BMJ Open 13(1):e062079

Article  Google Scholar 

Altundag MK, Celik I, Ozisik Y (2000) Is there a range of time for initiation of adjuvant chemotherapy in patients with malignancy? Ann Oncol 11(9):1209

Article  PubMed  CAS  Google Scholar 

Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V et al (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744

Article  PubMed  Google Scholar 

Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA (1982) Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 2(2):163–169

Article  PubMed  CAS  Google Scholar 

Shannon C, Ashley S, Smith IE (2003) Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol 21(20):3792–3797

Article  PubMed  CAS  Google Scholar 

Cold S, During M, Ewertz M, Knoop A, Moller S (2005) Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish breast cancer cooperative group (DBCG). Br J Cancer 93(6):627–632

Article  PubMed  PubMed Central  CAS  Google Scholar 

Al-Masri M, Aljalabneh B, Al-Najjar H, Al-Shamaileh T (2021) Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes. Breast Cancer Res Treat 186(1):7–13

Article  PubMed  Google Scholar 

Sanford RA, Lei X, Barcenas CH, Mittendorf EA, Caudle AS, Valero V et al (2016) Impact of time from completion of neoadjuvant chemotherapy to surgery on survival outcomes in breast cancer patients. Ann Surg Oncol 23(5):1515–1521

Article  PubMed  Google Scholar 

Eastman A, Tammaro Y, Moldrem A, Andrews V, Huth J, Euhus D et al (2013) Outcomes of delays in time to treatment in triple negative breast cancer. Ann Surg Oncol 20(6):1880–1885

Article  PubMed  Google Scholar 

Larson KE, Grobmyer SR, Karafa M, Pratt D (2018) Time to treatment and survival in triple negative breast cancer patients receiving trimodality treatment in the United States. Cancer Treat Res Commun 16:32–37

Article  PubMed  CAS  Google Scholar 

Tang A, Mittal A, Mooney CM, Khoury AL, Chiang A, Lai N et al (2022) Factors delaying chemotherapy in patients with breast cancer at a safety-net hospital. J Natl Med Assoc 113(6):706–712

PubMed  Google Scholar 

Kim IY, Kim BR, Kim YW (2015) Factors affecting use and delay (>/=8 weeks) of adjuvant chemotherapy after colorectal cancer surgery and the impact of chemotherapy-use and delay on oncologic outcomes. PLoS ONE 10(9):e0138720

Article  PubMed  PubMed Central  Google Scholar 

Meyer C, Bailleux C, Chamorey E, Schiappa R, Delpech Y, Dejode M et al (2022) Factors involved in delaying initiation of adjuvant chemotherapy after breast cancer surgery. Clin Breast Cancer 22(2):121–126

Article  PubMed  CAS  Google Scholar